Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 8/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 8/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 8/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483326 | 0.82 | DRD4 (0.50) | GRIN2DGRIN3BADRA1AGRIN1GRIN2A | |
| SCHEMBL7369953 | 0.82 | EPHX1 (0.57) | TAAR1SLC6A2 | |
| SCHEMBL3594490 | 0.82 | EPHX1 (0.57) | TAAR1SLC6A2 | |
| SCHEMBL3595876 | 0.82 | EPHX1 (0.57) | TAAR1SLC6A2 | |
| SCHEMBL1755597 | 0.82 | ALOX15 (0.47) | TAAR1SLC6A2OPRK1SLC7A5ADRA1A | |
| Hydrochloric Acid SCHEMBL5757770 | 0.81 | SLC6A4 (0.58) | SLC6A2DPP4 | |
| SCHEMBL13405058 | 0.81 | EPHX1 (0.55) | — | |
| Hydrochloric Acid SCHEMBL6007251 | 0.81 | EPHX1 (0.55) | SLC6A2 | |
| SCHEMBL11991373 | 0.81 | EPHX1 (0.55) | — | |
| Hydrochloric Acid SCHEMBL4350813 | 0.81 | EPHX1 (0.55) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266968-B1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORP (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2067775-B1 | A N-Acylsphingosine glucosyltransferase inhibitor | GENZYME CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1409467-B1 | A N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITOR | GENZYME CORP (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8138353-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2266968-A2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7763738-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7615573-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-10 | — | — | US | disclosed |
| EP-2067775-A1 | Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | HIRTH BRADFORD H | 2008-03-06 | — | — | US | disclosed |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-08-30 | — | — | US | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TAAR1 4553/4885SLC6A2 436/4885SMYD3 1202/4885 |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | TAAR1 4553/4885SLC6A2 436/4885SMYD3 1202/4885 |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | UGCG, UGGT1, LCLAT1 | TAAR1 3760/4885SLC6A2 1402/4885SMYD3 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.